Central Nervous System Biomarkers Market Report 2026

Central Nervous System Biomarkers Market Overview

• Central Nervous System Biomarkers market size has reached to $6.14 billion in 2025 • Expected to grow to $9.92 billion in 2030 at a compound annual growth rate (CAGR) of 10.2% • Growth Driver: The Surge In Neurological Illnesses And The Central Nervous System Biomarker Market • Market Trend: Revolutionizing Central Nervous System Biomarker Detection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Central Nervous System Biomarkers Market?

Central nervous system (CNS) biomarkers refer to specific substances or measurable indicators in the CNS that provide information about normal functioning, disease processes, or responses to treatments within the CNS. These are used to diagnose or predict neurological disorders, monitor disease progression, and predict responses to drug therapy. The main types of central nervous system biomarkers are safety biomarkers, efficacy biomarkers, validation biomarkers, and others. A safety biomarker refers to a measurable biological parameter or indicator used to assess the safety of a drug, medical intervention, or environmental exposure. These are used to treat several diseases, such as multiple sclerosis, Alzheimer's disease, traumatic brain injury, and others, through various applications, including drug discovery and development, personalized medicines, disease risk assessment, diagnostics, and others. Several end-users are included, such as diagnostic labs, clinics, hospitals, research centers, and others.

What Is The Central Nervous System Biomarkers Market Growth Forecast?

The central nervous system biomarkers market size is expected to see rapid growth in the next few years. It will grow to $9.92 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing investments in precision neurology, rising use of biomarkers in personalized medicine, growing adoption of ai-driven biomarker discovery, expansion of biomarker-guided clinical trials, increasing regulatory acceptance of biomarker endpoints. Major trends in the forecast period include increasing adoption of blood-based cns biomarkers, growing use of biomarkers in drug development pipelines, rising focus on early neurodegenerative disease detection, expansion of companion diagnostic biomarkers, enhanced integration of multi-omics data.

Global Central Nervous System Biomarkers Market Segmentation

1) By Type: Safety Biomarker, Efficacy Biomarker, Validation Biomarker, Other Types 2) By Disease: Multiple Sclerosis, Alzheimer's Disease, Parkinson's Disease, Traumatic Brain Injury, Other Diseases 3) By Application: Drug Discovery And Development, Personalized Medicines, Disease Risk Assessment, Diagnostics, Other Applications 4) By End-Users: Diagnostic Labs, Clinics, Hospitals, Research Centers, Other End-Users Subsegments: 1) By Safety Biomarker: Toxicity Biomarkers, Adverse Event Biomarkers 2) By Efficacy Biomarker: Pharmacodynamic Biomarkers, Response Biomarkers 3) By Validation Biomarker: Predictive Biomarkers, Prognostic Biomarkers 4) By Other Types: Diagnostic Biomarkers, Biomarkers For Disease Progression

What Is The Driver Of The Central Nervous System Biomarkers Market?

The rise in neurological illnesses is expected to propel the growth of the central nervous system biomarker market going forward. Neurological illnesses, also known as neurological disorders, refer to a broad range of conditions that affect the brain, spinal cord, and nerves throughout the body. These disorders can arise from various causes, including genetic factors, infections, autoimmune responses, degenerative processes, tumors, vascular issues, and traumatic injuries. In neurological disorders, central nervous system (CNS) biomarkers aid clinical diagnosis, determine illness risk or prognosis, assess disease stage, and track treatment response. They play a significant role in understanding these diseases and their ability to be treated. For instance, in April 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, Alzheimer's disease affected an estimated 6.7 million Americans aged 65 and older. This number is expected to nearly triple to 14 million by 2060. Moreover, the number of people living with the disease doubles every five years after age 65. Therefore, the rise in neurological illnesses drives the growth of the central nervous system biomarker industry.

Key Players In The Global Central Nervous System Biomarkers Market

Major companies operating in the central nervous system biomarkers market are F. Hoffmann-La Roche AG, Novartis AG, Siemens Healthineers, Thermo Fisher Scientific Inc, Abbott Laboratories, Merck KGaA, Eurofins Scientific, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Axon Neuroscience SE, Alector Inc., Oryzon Genomics S.A., Banyan Biomarkers Inc., Anavex Life Sciences Corp., Applied Neurosolutions Inc., C2N Diagnostics, Alzheon Inc., DiaGenic ASA, Avid Radiopharmaceuticals Inc., Cassava Sciences Inc.

Global Central Nervous System Biomarkers Market Trends and Insights

Major companies operating in the central nervous system biomarker market are focused on introducing next-generation solutions, such as assay kit. An assay kit is a pre-packaged set of reagents and materials used to conduct a specific scientific analysis. For Instance, In June 2023, Sysmex Corporation, a Japan-based research and development company, launched an Automated Immunoassay System. The assay kit is designed to identify amyloid beta (Aβ) accumulation in the brain, which is a cause of Alzheimer's disease, using a small amount of blood. The kit measures the ratio of Aβ peptides in the blood using an automated immunoassay system. It helps clinicians identify Aβ accumulation in the brain using a small amount of blood, allowing for earlier diagnosis and treatment for patients.

What Are Latest Mergers And Acquisitions In The Central Nervous System Biomarkers Market?

In February 2024, Quanterix, a US-based life sciences company, its first collaborations with five health networks to support the diagnosis and clinical management of individuals with Alzheimer’s disease. The partnerships aim to enhance early detection, improve patient care, and advance the use of biomarker-based diagnostics in clinical settings, while driving innovation and growth in the neurodegenerative disease diagnostics market. The collaborating health networks are leading providers of clinical care and research in neurology and dementia management.

Regional Outlook

North America was the largest region in the central nervous system biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Central Nervous System Biomarkers Market?

The central nervous system biomarkers market consists of sales of diagnostic test kits, assay reagents, antibody drugs, and imaging agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Central Nervous System Biomarkers Market Report 2026?

The central nervous system biomarkers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the central nervous system biomarkers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.